Liver resection for metastases from renal cell carcinoma.

Departmant of General, Visceral and Transplantation Surgery, Campus Virchow-Klinikum, Charité Universitaetsmedizin Berlin, Berlin, Germany.
World Journal of Surgery (Impact Factor: 2.23). 05/2007; 31(4):802-7. DOI: 10.1007/s00268-007-0685-9
Source: PubMed

ABSTRACT This study was conducted to evaluate the safety and efficacy of liver resection in patients with hepatic metastases from renal cell carcinoma and to identify selection criteria for patients suitable for resection.
Between January 1988 and March 2006, 31 patients underwent liver resection for metastases from renal cell carcinoma. Patients were identified from a prospective database and retrospectively reviewed. Patient, tumor, and operative parameters were analyzed for their influence on long-term survival.
The overall 1-, 3- and 5-year survival rates were 82.2%, 54.3%, and 38.9%, respectively. One patient was deceased and 4 developed complications during the postoperative course. In the univariate analysis, site of the primary tumor (P = 0.013), disease-free interval (P = 0.012), and resection margins (P = 0.008) showed significant influence on long-term survival. In the multivariate analysis, only the resection margins were identified as an independent prognostic factor after liver resection.
Liver resection is effective and safe in the treatment of patients with hepatic metastases from renal cell carcinoma and offers the chance of long-term survival and cure. Achieving a margin-negative resection is the most important criterion in the selection of suitable patients for liver resection. However, the number of patients in the present study was small, and investigations of larger series may provide further prognostic parameters in these patients.

  • [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE: To retrospectively analyze the clinical outcome of patients with hepatic metastases from renal cell carcinoma who were treated with computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT). METHODS: Ten patients (7 men and 3 women; median age 72 ± 7.9 years) with a total number of 16 hepatic metastases from histologically proven renal cell carcinoma were treated with CT-HDRBT after discussing the case in an interdisciplinary tumor conference. All patients had underwent nephrectomy before CT-HDRBT. Three patients had extrahepatic manifestations (2 lung and 1 bone). Six patients had received immunotherapy or targeted therapy before CT-HDRBT. Follow-up included gadoxetic acid (Gd-EOB-DTPA) enhanced MRI two times within 6-8 weeks and after that every 3 months after treatment to evaluate treatment efficacy. RESULTS: Mean follow-up time was 21.6 ± 13.7 months. One patient developed local and systemic (pulmonary and osseous) progression after 10.8 months which was treated with targeted therapy and died 20.3 months after CT-HDRBT. None of the remaining nine patients developed local progression or died during the follow-up period. Five patients developed systemic progression (3 pulmonary, 1 osseous and 1 locally at the site of nephrectomy) after an average of 19.7 ± 5.5 months. CONCLUSIONS: CT-HDRBT is a viable alternative to hepatic resection of liver metastases from renal cell carcinoma in selected patients.
    World Journal of Urology 11/2012; · 2.89 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hintergrund Die Metastasenresektion wird vor oder nach einer systemischen Therapie im Rahmen eines multimodalen Therapiekonzepts beim metastasierten Nierenzellkarzinom (mNZK) durchgeführt. Unter welchen Voraussetzungen die Prognose durch diese Resektion verbessert wird, wird kontrovers diskutiert. Ziel dieser Arbeit ist es, die publizierten Daten diesbezüglich zu sichten und kritisch zusammenzufassen. Methode Es wurde eine systematische MedLine-Recherche bezüglich Metastasenresektion bei mNZK durchgeführt. Original publizierte Daten, Reviews und Editorials wurden in diese Übersicht einbezogen. Weiterhin wurden die aktuellen Europäischen Guidelines berücksichtigt. Ergebnisse Eine Resektion von Metastasen beim mNZK sollte durchgeführt werden, wenn eine stabile Erkrankung mindestens über 3 Monate vorliegt, eine komplette Resektion möglich ist und ein guter Performancestatus des Patienten vorliegt. Die mittlere Überlebenszeit reicht nach Resektion von 35–55 Monate. Schlussfolgerung Beim mNZK ist die Metastasenresektion eine Therapieoption die bei günstigen Prognosefaktoren das mittlere Überleben verlängern kann. Die Metastasenresektion sollte einen festen Stellenwert für geeignete Patienten in der multimodalen Therapie haben.
    Der Urologe 51(9). · 0.46 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The term 'oligometastases' was formulated to describe an intermediate state between widespread metastases and locally confined disease. The standard of care in metastatic renal cell carcinoma is systemic therapy; however, in patients with solitary or limited metastases, aggressive local therapies may potentially prolong survival. The literature suggests a survival benefit with surgical metastasectomy, with a reported 5-year survival as high as 45% in those who achieve complete resection. More recently, an expanding body of evidence supports the role of stereotactic ablative body radiation therapy for the treatment of oligometastatic renal cell carcinoma and early results demonstrate comparable local control rates with surgery. There is also increasing interest in the abscopal and immunologic effects of localized radiation. With the proliferation of newer targeted agents and immunomodulatory agents, current work is addressing the optimization of patient selection and avenues towards sequencing and combining the various treatment options.
    Future Oncology 04/2014; 10(5):761-74. · 3.20 Impact Factor